Covid Alert


Print ISSN:-2395-1443

Online ISSN:-2395-1451

CODEN : IJCEKF

Current Issue

Year 2020

Volume: 6 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 97

Emailed: 0

PDF Downloaded: 68


Soni, Sethia, Mehta, Patel, and Vyas: To study correlation of HbA1c and macular thickness changes in diabetic patients after phacoemulsification and small incision cataract surgery (SICS)


Introduction

Diabetes mellitus (DM) is well-known for causing multiple organ damage and life-threatening outcomes due to abnormal small vessel formation. Diabetic retinopathy (DR) is one of the manifestations of chronic diabetes causing leakage and neovascularization.1 Since many decades, the diagnos is of DM is based on either fasting plasma glucose levels or 2 hours postprandial glucose levels. It was only in 2010 that plasma glycosylated haemoglobin or HbA1c ≥ 6.5% was accepted by the American Diabetes Association as cut-off for DM an this modality helps to evaluate the glycosylated Hb over the past 3 months. It is now proved that HbA1c levels are better predicators of DR than any other routinely employed tests. DR can manifest in multiple forms as retinal haemorrhages, ischemia, neovascularization, and macular edema especially with poorly controlled HbA1c levels and long standing DM.2 Out of these, macular edema is the most important predictor of poor visual outcome in diabetics, particularly after cataract surgery.3 It shows a higher incidence of macular edema (DME) which can either be ascribed to new vessel formation or immediate post- operative inflammation.4 Optical coherence tomography (OCT) is a easy, quick, non-invasive tool that is immensely useful to an ophthalmologist to evaluate neovascularisation and assess the status of the macula. The central macular thickness(CMT) or foveal thickness is used to measure macular edema in DR and DME being the most common cause for sub-optimal visual outcome after routinely performed lens surgeries.5 This research focuses on the influence of HbA1c levels on foveal thickness pre and post uncomplicated phacoemulsification and SICS surgeries.

Materials and Methods

This was a retrospective study conducted in the Ophthalmology department of Dhiraj Hospital, Vadodara. A total of 100 patients with type 2 DM were enrolled with us, out of which 50 patients underwent uncomplicated phacoemulsification with acrylic hydrophilic foldable IOL implantation and rest 50 underwent uncomplicated SICS with rigid PMMA IOL implantation . All the surgeries were performed by a single surgeon with uniform pre and postoperative protocol. All the participants gave informed consent before the study. The study also adhered to the tenets of the Declaration of Helsinki. The study was reviewed and approved by the institutional Ethics Committee of our hospital.

Patients known to have type II diabetes with mild to moderate Non-Proliferative Diabetic Retinopathy (NPDR), without pre-existing macular edema (on OCT, macular thickness of <280 microns) and co-existing senile cataract with nuclear sclerosis grade II to IV were included in our study. None had a history of the previous laser or intravitreal injections. The patients were subdivided into 3 groups based on their HbA1c levels as follows: Group 1 - HbA1c <6.5 %, Group 2-6.5 to 8% and Group 3 : >8%. The fasting blood sugar levels (FBS) and postprandial blood sugar(PPBS) levels were also measured pre and post-operatively in all patients who were already on diabetic treatment.

A complete ophthalmic workup including visual assessment using Snellen's chart(best corrected visual acuity) which was then converted to LogMAR for analysis, slit-lamp examination and tonometry were also done. The cataract grading was based on the LOCS III classification. Diabetic retinopathy evaluation was done by viewing dilated posterior segment, both pre and postoperatively on day 1, day 7, 1 month and 3 months. Optical Coherence Tomography (Topcon 3D OCT 1000) was also done preoperatively & postoperatively to measure foveal thickness by ETDRS grid. Three-dimensional macular thickness map analysis program was used to measure retinal thickness values in the fovea, parafoveal and perifoveal areas. Parafoveal areas were defined as the area between central 1-mm circle and the surrounding circle with 3-mm diameter (i.e. area between 1- and 3- mm diameters) in four equal quadrants (i.e. superior, inferior, temporal, and nasal), while perifoveal areas were defined as the area between parafoveal and surrounding circle of 2 mm width. OCT analysis of each map was done to find cystic spaces or diffuse retinal thickening.

Group 1- Phacoemulsification through a standard 2.8 mm of limbal incision was done and foldable PCIOL was implanted in 50 eyes . We used Catarhex easy machine by Oertli for phacoemulsification . The average phaco power was between 50%-60% and absolute phaco time was 15 .9 ± 7 seconds while the entire procedure took 14.5± 5.5 minutes.

Group 2- Manual SICS was done through a 5.5 to 6.5 mm incision with sclerocorneal tunnel and PMMA PCIOL was implanted in 50 eyes. The average SICS time was 12.7± 6.5 minutes.

All the surgeries were uneventful and same post-operative medications were used in both the groups after surgery. (steroid-antibiotic combination eyedrops were used 4 times a day for one week followed by 3,2,1 weekly tapering in operated eye).

Statistical analysis

All the results are expressed as the number, percentage and mean ± standard deviation(SD). Average Central Macular Thickness (CMT) between the two groups (phaco and SICS) was calculated and tabulated. Data was statistically analysed using Student’s t-test. P-value <0.05 was considered as significant level. SPSS 2.0 was used for post hoc statistical analysis.

Results

Our study included 100 eyes of 100 patients, 50 underwent SICS and 50 patients underwent phacoemulsification procedure. Out of them, 33 patients belonged to group 1, 34 belonged to group 2 and 33 belonged to group 3 (Table 1). Intergroup variation in preoperative macular thickness was found to be statistically insignificant between SICS and PHACO groups.

Table 1
Parameters Group 1 (<6.5) Group 2 (6.5 – 8) Group 3 (>8) P
BCVA (LogMAR) Phaco 0.75±0.420 0.82±0.34 0.84±0.39 0.002
Sics 0.83±0.753 0.73±0.23 0.93±0.77 0.048
Age (year) Phaco 55.06±9.77 54.13±4.23 62.67±8.33 NS
Sics 57.39±10.54 60.56±6.44 68.93±11.35 NS
Gender (Male/Female) Phaco 7/9 8/9 8/9 NS
Sics 8/9 9/8 10/6 NS
CMTμm (±SD)( Preop) Phaco 193.00±31.11μ 220.50±49.32μ 225.19±23.77μ 0.554
Sics 188.00±35.76 232.43±41.68 235.98±25.45 0.498
HbA1c (mean±SD) Phaco 4.92±1.58 7.41±1.45 9.84±1.23 0.001
Sics 5.03±1.88 7.73±1.23 9.43±1.08 0.028

Demographics and Preoperative information of all subjects

A higher value of foveal thickness was observed in the SICS group than PHACO group during follow up. The highest and significant difference in macular thickness was found in group C on day 7 (251.54±22.68 μm, p =0.015), 1 month(267.46±43.44 μm, p=0.031) and 3 months (260.75±48.44 μm, p=0.002) postoperatively in SICS patients. The foveal thickness resolved to near normal in the group A, but group B and C respectively showed a significant (p =0.005) difference during the final follow up on 3 months follow up, with a value of 240.72 ± 65.81 μm and 237.19 ± 40.70 μm in group B and C for PHACO patients and a 251.50 ± 59.36 μm and 260.75 ± 48.44 μm in SICS. (Table 2).

Thus, glycemic index plays an important role in predicting the macular thickness post-operatively especially in patients undergoing SICS while phaco group showed return of macular thickness to baseline by 3 months. (Table 3).

Table 3
HbA1c Group Code Mean SD p value
<6.5 (N=16) Baseline Phaco 193.00 31.113 P = 0.422
Sics 201.50 28.515
POD 1 Phaco 210.00 49.497 P = 0.126
Sics 221.73 35.465
POD 7 Phaco 205.50 30.406 P = 0.056
Sics 219.00 39.465
POD 1 MONTH Phaco 212.50 19.092 P = 0.040
Sics 226.00 16.433
POD 3 MONTHS Phaco 195.00 33.941 P = 0.067
Sics 211.00 37.476
6.5 – 8 (N=18) Baseline Phaco 220.50 49.320 P = 0.353
Sics 232.60 44.213
POD 1 Phaco 240.39 57.998 P = 0.027
Sics 252.86 53.826
POD 7 Phaco 243.83 51.903 P = 0.043
Sics 257.86 58.623
POD 1 MONTH Phaco 260.83 72.989 P = 0.427
Sics 264.65 66.167
POD 3 MONTHS Phaco 240.72 65.806 P = 0.028
Sics 251.50 59.367
>8 (N=16) Baseline Phaco 225.19 23.772 P = 0.546
Sics 223.64 27.578
POD 1 Phaco 226.13 28.714 P = 0.044
Sics 238.63 24.578
POD 7 Phaco 230.44 26.470 P = 0.002
Sics 251.54 22.687
POD 1 MONTH Phaco 244.50 37.299 P = 0.003
Sics 267.46 43.443
POD 3 MONTHS Phaco 237.19 40.696 P = 0.002
Sics 260.75 48.443

Comparision of foveal thickness in each group pre and postop

There was no statistically notable difference in pre and postoperative BCVA for all three groups. On post-operative 3 month, BCVA was comparible between SICS and phaco patients (p=0.322, p=0.441, p=0.284 respectively) and there appears to be no association between the best corrected visual acuity (BCVA) and different levels of HbA1c. (Table 4)

Table 4
HbA1c Group Code Mean LogMAR SD p value
<6.5 (N=16) Baseline Phaco 0.75 0.420 P = 0.089
Sics 0.67 0.120
POD 1 Phaco 0.22 0.140 P = 0.438
Sics 0.27 0.180
POD 7 Phaco 0.15 0.100 P = 0.485
Sics 0.18 0.060
POD 1 MONTH Phaco 0.12 0.800 P = 0.067
Sics 0.18 0.140
POD 3 MONTHS Phaco 0.10 0.008 P = 0.322
Sics 0.16 0.160
6.5 – 8 (N=18) Baseline Phaco 0.82 0.340 P = 0.497
Sics 0.80 0.360
POD 1 Phaco 0.23 0.170 P = 0.362
Sics 0.20 0.070
POD 7 Phaco 0.19 0.110 P = 0.495
Sics 0.16 0.270
POD 1 MONTH Phaco 0.1 0.090 P = 0.442
Sics 0.13 0.110
POD 3 MONTHS Phaco 0.06 0.080 P = 0.441
Sics 0.09 0.060
>8 (N=16) Baseline Phaco 0.84 0.390 P = 0.262
Sics 0.76 0.040
POD 1 Phaco 0.21 0.140 P = 0.354
Sics 0.16 0.160
POD 7 Phaco 0.19 0.100 P = 0.120
Sics 0.14 0.090
POD 1 MONTH Phaco 0.11 0.060 P = 0.234
Sics 0.09 0.040
POD 3 MONTHS Phaco 0.09 0.020 P = 0.284
Sics 0.08 0.030

Comparison of BCVA in each group

Discussion

Most of the cataract surgeries are associated with post-operative inflammation due to disruption of the blood-retina barrier (BRB) which leads to increased capillary permeability from the perifoveal network and fluid accumulation within retina, both intra and extracellular. One of the oldest and most commonly performed cataract procedure-Small Incision Cataract Surgery (SICS) has a larger incision, higher chances of damage to iris, and increased intra-operative tissue manipulation thereby, higher chances of inflammation. A newer modality of treatment-Phacoemulsification is a closed chamber surgery, causes lesser damage to ocular structures and anterior chamber reaction when done well. However, there is no evidence as to the significance of HbA1C control on the macular thickness of diabetic patients following cataract surgery.

Rostos et al in their review study suggested that when diabetic patients undergo cataract surgery, it might accelerate pre-existing diabetic macular oedema leading to poor visual outcome.7, 6 Some other researchers have also suggested that even in the absence of pre-existing DME, diabetic patients tend to have a higher propensity of developing DME after uncomplicated cataract surgery.8

Analysis done over the years between PHACO and SICS procedures showed that the macular thickness was higher in SICS group. Many authors showed significant difference in macular thickness between PHACO and SICS group on 3 rd day, 7th day, 3rd month and 6 months post-operative follow ups. 9 A study done by Dr. Indranil Roy et al on total 224 patients who were randomised to two groups- phaco and SICS, found mean central foveal thickness in SICS group was more than that of phaco group on post-op 1st, 7th, 42nd and 180th day. On day 180, mean central foveal thickness in SICS group was significantly (p=0.032) more than phaco group.10 Another study conducted by Dr. Dimpy et al on 100 eyes undergoing manual SICS showed that macular thickness was comparable preop and day 1 postop, while CMT increased in all patients at 4 weeks and 8 weeks and returned to near baseline values in most of the patients by 12 weeks.11

CME is the accepted as one of the frequent causes for suboptimal visual outcome after cataract surgeries and constitutes the most common cause of un predicted vision loss after many ocular procedures according to a research by Ray and D ’Amico et al in 2002.5 Loewenstein and Zur et al (2010)12 reported a rate of clinical CME as 0.1-2.35% following modern cataract extraction procedures.13

Our study found a significant increase in CMT in SICS group as compared to phacoemulsification on postoperative day 7(p=0.015), 1 month (p=0.031) and 3 months (p=0.002) in group C. An increase in macular thickness was also noted in group B(p=0.043) on POD 7 which returned to near normal values by 1 month and showed no significant difference (p= 0.427). Also group A showed no significant change in CMT on all post-operative days due to their well-controlled sugar levels, and only a non-significant difference was noted between SICS and phaco groups on POD 7 and 1 month. This indicated a strong correlation between poorly controlled HbA1C levels, causing significant visual morbidity postoperatively.

A similar correlation of HbA1c and postoperative macular edema in eyes with diabetic retinopathy was noted after phacoemulsification and SICS for as long as 12 months.14 Progression of DR can be slowed down with judicious use of medications for controlling blood glucose levels and hyperlipidaemia according to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.15 The Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR)16 showed that poorly controlled HbA1c levels with higher fluctuations in blood glucose levels increased the incidence of DM E over a 10-year period (Klein et al. 1995)12. The Diabetes Control and Complication trial (DCCT)17 and the UK Prospective Diabetic Study (UKPDS),18 both of which were prospective randomized studies, showed that intensive glycaemic control and reduction of HbA1c levels are associated with a decrease in the rates of development as well as progression of diabetic retinopathy (DR) and DM E. OCT was utilized for more precise qualitative and quantitative assessment of macular thickness pre- and postoperatively.

In our study, the visual acuity did not deteriorate even if the macular thickness increased at 1 month postoperatively because removal of cataract caused significant clarity in visual axis of patient. Good visual acuity persisted even at 3 months postoperatively in both SICS and phaco group. According to Eriksson et al, changes in macula occurring post-operatively is only transient in the short-term (6 weeks), even if patient has DR , and final visual outcome is non-inferior.15 Therefore, diabetic patients may not show significant difference from the nondiabetic patients when we evaluate the short- term post-cataract surgery visual recovery. A reduction of HbA1c levels from 7.9% to 7.0% in type 2 diabetes resulted in reduction in the frequency of laser treatments needed.18 In type 1 patients, a reduction of HbA1c values from 9.1% to 7.1% and improved blood glucose control reduced the risk of developing DR by 76% within 6.5 years, the risk of DR progression by 54%, and the risk of developing proliferative diabetic retinopathy (PDR) by 47%.19 Therefore, an optimal level of less than or equal to 7% HbA1c levels should be aimed for an individual patient, from an ophthalmologist’s point of view.20 DCCT mentions the risk of developing CSME to be 23% for those patients who are on long term insulin treatments. The incidence of pseudopakic cystoid macular edema rang es from 1%–30% depending on the risk factors defined for an individual, but the incidence remains on a higher side for diabetics. Unsal et al21 observed that the mean CMT (371 μm) in eyes with DME was significantly higher than the eyes with PDR (256 μm) and Non-Proliferative Diabetic Retinopathy (NPDR) (253 μm). Another study in contrast to our research states that no correlation exists between HbA1c levels and CMT in patients undergoing phacoemulsification.22 The limitations of this study include shorter duration of follow-up (3 months), small sample size and duration of diabetes.

Conclusion

In this study, we found a correlation between HbA1c levels and macular thickness in diabetics undergoing phacoemulsification and SICS. A large number of patients undergoing SICS and belonging to group C showed a significant increase in central foveal thickness, beginning from 1st postoperative day till 3 months, but phacoemulsification group showed only slight increase in foveal thickness on postoperative 1 month which returned to near baseline levels by 3 months post-operatively. This indicates phacoemulsification procedure as an excellent choice for cataract removal in diabetics, thus avoiding unwanted complications. However, HbA1c levels had no correlation with the final outcome in BCVA in our study.

Source of Funding

None.

Conflict of Interest

None.

References

1 

W Todd Cade Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy SettingPhys Ther2008881113221335

2 

Rehab Benarous Muhammad B. Sasongko Salmaan Qureshi Eva Fenwick Mohamed Dirani Tien Y. Wong Differential Association of Serum Lipids with Diabetic Retinopathy and Diabetic Macular EdemaInvest Ophthalmol Vis Sci2011521074647464

3 

Marieke Criel Stijn Jonckheere Michel Langlois Evaluation of Three Hemoglobin A1c Point-of-Care InstrumentsClin Lab201662285291

4 

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of DiabetesDiabetes Care200932713271334

5 

S Ray D Amico D J Pseudophakic cystoid macular edemaSemin Ophthalmol2002173-4167180

6 

T G Rostos M M Moschos Cystoid macular edemaClin Ophthalmol200824919930

7 

S Sood S Narang Evaluation of macular thickness after uncomplicated phacoemulsification using OCTAIOC2009

8 

T C Fenandez-Blanco O Ruiz-Moreno E Ferrer-Novella Pseudophakic cystoid macular edema assessment with OCTArch Soc Esp oftalmol2006813147154

9 

P Mandal S R Srivastava Macular Thickness, OCT, Phacoemulsification, SICS. Comparative evaluation of macular thickness after phacoemulsification vs manual sics by ocular coherence tomography in diabetic patients2016https://jebmh.com/latest_articles/95409

10 

I Roy P N Biswas S Ghosh Prospective randomized comparative study of macular thickness by OCT following phacoemulsification & manual SICSAIOC2009

11 

D Gothwal T Grover A Grover Incidence of CME following manual SICS using OCTAIOC2009

12 

A Loewenstein D Zur Postsurgical cystoid macular edemaDev Ophthalmol201047148159

13 

K Hayashi C Igarashi A Hirata H Hayashi Changes in diabetic macular oedema after phacoemulsification surgeryEye (Lond)200923389396

14 

E Y Chew W T Ambrosius M D Davis R P Danis S Gangaputra C M Greven Effects of medical therapies on retinopathy progression in type 2 diabetesN Engl J Med20103633233244

15 

Ronald Klein Barbara E.K. Klein Scot E. Moss Karen J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy XVOphthalmol19951021716

16 

J M Lachin S Genuth P Cleary M D Davis D M Nathan Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupN Engl J Med2000342381389

17 

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837853

18 

D M Nathan S Genuth J Lachin P Cleary O Crofford M Davis The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329977986

19 

Martin M Nentwich Diabetic retinopathy - ocular complications of diabetes mellitusWorld J Diabetes201563489499

20 

Erkan Unsal Kadir Eltutar Sibel Zirtiloglu Nurhan Dincer Sezin Ozdogan Erkul Hulya Gungel Choroidal thickness in patients with diabetic retinopathyClin Ophthalmol20148637642

21 

R Sethia P K Mehta R Kothari V Desai A Soni A Correlation of Glycemic Index and Macular Thickness After Phacoemulsification in DiabeticsSci J Delhi Ophthalmol Soc20192943943



jats-html.xsl

© 2020 Published by Innovative Publication Creative Commons Attribution - NonCommercial 4.0 International (CC BY-NC 4.0) license (creativecommons.org)